Precision Oncology Market By Technology (Genomics, Transcriptomics, Proteomics, Epigenomics, Pharmacogenomics, Digital Pathology, and Bioinformatics), By Therapy Type (Targeted Therapy, Immunotherapy, Hormone Therapy, Chemotherapy, Radiotherapy, and Others), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma, and Others), By Biomarker Type (Genetic Biomarkers, Protein Biomarkers, Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), Epigenetic Biomarkers, Immune Biomarkers, and Others), By Application (Diagnostics, Prognostics, Therapeutics, Drug Development & Clinical Trials, and Monitoring & Recurrence Detection), and By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, and Contract Research Organizations (CROs)), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Precision Oncology Market in the coming years?

The Precision Oncology Market accounted for USD 116.43 Billion in 2024 and USD 125.88 Billion in 2025 is expected to reach USD 274.81 Billion by 2035, growing at a CAGR of around 8.12% between 2025 and 2035. The precision oncology market is oriented toward creating and delivering cancer cures based on the genetic composition of the specific tumour of the patient. It allows individualised therapies involving particular mutations by employing the latest technologies such as genomic sequencing and molecular diagnostics, which enhances the efficacy of the treatment and lowers side effects. These are diagnostic tools, targeted drugs, and supportive services in this market to improve patient outcomes. Its rapid growth is propelled by increasing awareness, technology, and increasing rates of cancer globally.

What do industry experts say about the Precision Oncology market trends?

“Precision oncology is redefining cancer care by targeting specific genetic mutations rather than tumor location, offering more effective and personalized treatments with fewer side effects.”

• Dr. José Baselga, MD, PhD (Former Chief Medical Officer, Oncology R&D, AstraZeneca)

“The integration of next-generation sequencing and molecular diagnostics into oncology allows us to match patients with the most appropriate targeted therapies, significantly improving outcomes.”

• Dr. Levi Garraway, MD, PhD (Chief Medical Officer, Roche/Genentech)

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Precision Oncology market?

How does genomic sequencing advancement boost precision oncology adoption?

Genomic sequencing has enhanced precision oncology, as therapies are now possible based on the individual genetic characteristics of a patient. According to the U.S. National Human Genome Research Institute, the cost of sequencing has decreased compared to almost $100 million in 2001 and is estimated to decline to approximately 600 in 2024, making sequencing more accessible to the clinic. Such government initiatives as the 100,000 Genomes Project in the UK demonstrate the use of large-scale sequencing to identify actionable mutations to inform specific therapies.

Investigations by the National Cancer Institute show that in up to 50% of advanced cancers, sequencing of tumours determines treatable mutations. The emphasis of investment and research into genomics in oncology, as presented by the U.S. Cancer Moonshot and the NHS Genomic Medicine Service, is a way to remove trial-and-error treatment and enhance patient outcomes. Moreover, an increased rate of sequencing turnaround can facilitate prompt therapeutic decisions, whereas the increasing capabilities of bioinformatics can facilitate the interpretation of complex genomic data, rendering precision oncology more realistic and effective in the daily practice of clinical care.

What role does growing biomarker availability play in market expansion?

The increasing number of biomarkers is greatly diversifying the precision oncology market, as it allows individualised therapies on the basis of genetic profiles. According to the U.S. National Cancer Institute (NCI), biomarkers play a critical role in determining patients who respond best to targeted therapies and enhancing the effectiveness of treatment, and reducing side effects. This change can be traced in more than 80 cancer drugs that are FDA-approved and carry biomarker-related indications. The 100,000 Genomes Project initiative by Genomics England and the NHS in the UK has been able to pinpoint some of the most important biomarkers related to cancer through the sequencing of patients' genomes, propelling genomics into clinical oncology.

In India, the IndiGen program led by CSIR sequenced over 1,000 genomes, which found over 55 million genetic variants – more than 30% unique – to support population-specific biomarker development. According to a report by the European Society of Medical Oncology (ESMO), biomarker-based targeted therapies are better than regular chemotherapy in terms of progression-free survival. Such government and academic initiatives are increasing access to biomarker testing and, in the process, increasing the pace of the precision oncology market all over the world.

Why is infrastructure inadequacy a barrier in developing countries?

Poor infrastructure in third-world countries is a major obstacle to the expansion of the precision oncology market because it restrains the necessary healthcare services and technologies to treat cancer in a personalised manner. Most facilities do not have access to clean water, sanitation, and electricity, which are essential in the safe use of complex diagnostic procedures and treatments.

WHO data indicates that low- and middle-income countries with approximately 38% of the health facilities have no better water sources, and almost 35% do not have handwashing facilities, which exposes people to high risks of infection and low-quality care. Precision medicine cannot be effectively achieved due to the lack of trained specialists in oncology and molecular diagnostic laboratories.

Oncologists are less than 1 per 100,000 population in many African countries, versus more than 10 per 100,000 in the high-income world. Inadequate transport systems also slow access of patients to specialised centres. Moreover, precision oncology is too costly for the majority of patients because of insufficient funding and ineffective healthcare systems. All these prevent the use of precision oncology faster, so the difference in cancer outcomes with other countries that are richer exists.

How can rising AI integration improve precision treatment outcomes?

Precision oncology is greatly enhanced by the integration of AI in its capabilities of performing accurate tumour profiling, early diagnosis, and the selection of targeted therapy. The National Cancer Institute (NCI) states that AI algorithms are being developed to detect cancer using automated image analysis, thus increasing the accuracy of the diagnostic process and minimizing the differences between clinicians. The work of Harvard Medical School on AI-powered pathology has shown more than 90% precision in the classification of cancer subtypes, assisting oncologists in choosing more potent therapy.

A research report by Nature Medicine (2020) demonstrated that an artificial intelligence model has significantly better performance when screening for breast cancer than the work of human radiologists, with reduced false positives and false negatives. Moreover, the FDA has already given approvals to several diagnostic tools developed on AI, which indicates an increasing confidence in the clinical worth that AI possesses. Such advances are establishing a strong base of precision oncology, where therapies are more closely tailored to the genetic and molecular profile of a patient, which will eventually enhance survival rates and limit overtreatment.

Why does expanding telemedicine access enhance service reach globally?

The increased access to telemedicine increases the reach of precision oncology services by bypassing geographic and structural barriers that tend to obstruct the delivery of timely cancer diagnosis and treatment. The government-sponsored eSanjeevani telemedicine programme in India has so far supported more than 340 million remote visits since 2019, making remote consultations reach even rural and underserved populations.

It works on a hub-and-spoke concept of over 125,000 primary health centres, which provide cancer patients with access to specialised oncologists without the need to travel. These projects show how telemedicine can be used to hasten the provision of personalised cancer treatment using genetic profiling, which is essential in successful treatment planning.

Tele-oncology has also proven to decrease time wastage in reviewing pathology and increase teamwork between specialists, which leads to better treatment outcomes, as indicated in academic literature. With the help of telehealth technologies, precision oncology will be able to target a broader patient base around the world, and no patients will be deprived of high-quality diagnostics and personalised treatment.

What are the key market segments in the Precision Oncology industry?

Based on the Technology, the Precision Oncology Market has been classified into Genomics, Transcriptomics, Proteomics, Epigenomics, Pharmacogenomics, Digital Pathology, and Bioinformatics. The largest and most prominent segment in the precision oncology market is genomics. The reason is that genomics allows the genetic mutations and the tumour profile of patients to be studied in detail, which is essential in determining specific targeted therapies based on the type of cancer. The next-generation sequencing (NGS) innovation has enhanced the faster application of genomic data to support individual treatment decisions to improve outcomes and reduce side effects. Although this process is helped by other technologies such as proteomics and bioinformatics, genomics has been the mainstay of precision oncology because it has a direct influence on molecular insights into cancer.

Based on the Therapy Type, the Precision Oncology Market has been classified into Targeted Therapy, Immunotherapy, Hormone Therapy, Chemotherapy, Radiotherapy, and Others. Targeted therapy is the most pronounced and important segment of the precision oncology market. This therapy concentrates on individual genetic defects and molecular targets in cancerous cells, which enables much personalised treatment and directly targets the tumour growth pathways, avoiding normal cells. Molecular diagnostics has boosted the use of targeted therapies since breakthroughs have resulted in improved patient outcomes with fewer side effects than conventional methods. Immunotherapy is quickly rising, yet targeted therapy is still predominant, as it has its position in precision medicine.

Which regions are leading the Precision Oncology market, and why?

The North American precision oncology market is dominated by because of its high level of healthcare facilities and heavy investments in research and development. An advantage comprises the availability of large pharmaceutical makers and biotechnological corporations that stimulate the progress of focused therapy and diagnostic devices. Regulatory frameworks that are well-established make it easier to approve precision medicine products more quickly. Market growth is further driven by high levels of patient and healthcare provider awareness and access to the best genomic technologies.

The growing incidence of cancer and the growing need to have individualised modes of treatment are also factors that lead to the dominance of North America. Close partnerships between education and players in the industry generate a continuous improvement of services, which consolidates the role of the region as a leader in precision oncology. Moreover, there is significant government funding and reimbursement policy in favour of precision oncology, which makes advanced treatment more affordable. The synergistic effect of this dynamic generates a strong ecosystem that is ever-accelerating market growth in North America.

The Asia Pacific precision oncology market is expanding because of a few major reasons. With the growing healthcare investments and the rapid progress in genomic research and biotechnology, personalised cancer treatment has gained popularity and is being adopted. Countries such as China, Japan, and South Korea are very much investing in precision medicine infrastructure, including the use of sophisticated diagnostic equipment and targeted therapies.

The increasing cancer rates, as well as an increased understanding of personalised treatment options, have put pressure on the precision of the oncology solutions. The market is further reinforced by favourable government policies, growing access to healthcare, and partnerships between universities and pharmaceutical firms.

The high and heterogeneous population of patients in the region also creates the opportunity to conduct wide-scale clinical trials and data generation that feeds innovation and market expansion. Overall, the blend of technological progress, strong healthcare initiatives, and demographic factors positions the Asia Pacific as a key leader in the global precision oncology landscape.

What does the competitive landscape of the Precision Oncology market look like?

The precision oncology market is very competitive, as companies such as AstraZeneca, Roche, Bristol-Myers Squibb, Illumina, and Guardant Health are vying and advancing innovations by using strategic acquisitions and partnerships. Recently, AstraZeneca has been boosting its gene editing and targeted therapy pipeline through the acquisition of special biotech companies and its activities in blood cancer treatments. Roche is still using its robust diagnostics portfolio to incorporate the use of sophisticated molecular profiling into personalised cancer treatment.

Bristol-Myers Squibb is also investing in AI-based clinical trials to develop drugs faster and better stratify patients. On the diagnostics side, Illumina is exploring the limits of the next-generation sequencing technology, and Guardant Health is the first to innovate liquid biopsy approaches to make tumour monitoring non-invasive. Smaller companies such as Caris Life Sciences and Myriad Genetics are also on the rise, providing end-to-end genomic profiling services. Such joint ventures and technologies are driving the market to even more accurate, efficient, and individualised oncology therapies.

Precision Oncology Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Precision Oncology industry?

• In May 2025, England’s NHS became the first health system in the world to launch a national liquid biopsy service using a DNA blood test-first approach for lung and breast cancer. The test analyzed circulating tumor DNA (ctDNA) to help guide personalized treatment decisions, providing faster results, reducing invasive procedures, and potentially saving £11 million each year.
• In August 2025, GlaxoSmithKline (GSK) re-entered India’s oncology market by launching two precision drugs, Jemperli (dostarlimab) and Zejula (niraparib), aimed at treating gynecological cancers. These targeted therapies highlighted GSK’s renewed commitment to precision oncology.

Report Coverage:

By Technology

• Genomics
• Transcriptomics
• Proteomics
• Epigenomics
• Pharmacogenomics
• Digital Pathology
• Bioinformatics

By Therapy Type

• Targeted Therapy
• Immunotherapy
• Hormone Therapy
• Chemotherapy
• Radiotherapy
• Others

By Cancer Type

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Lymphoma
• Others

By Biomarker Type

• Genetic Biomarkers
• Protein Biomarkers
• Circulating Tumor DNA (ctDNA)
• Circulating Tumor Cells (CTCs)
• Epigenetic Biomarkers
• Immune Biomarkers
• Others

By Application

• Diagnostics
• Prognostics
• Therapeutics
• Drug Development & Clinical Trials
• Monitoring & Recurrence Detection

By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutions
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb
• Caris Life Sciences
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• Johnson & Johnson
• Laboratory Corporation of America Holdings (LabCorp)
• Merck & Co.
• Myriad Genetics, Inc.
• Qiagen N.V.

Frequently Asked Questions (FAQs)